Back to Sectors

TARS

Tarsus Pharmaceuticals, Inc.
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

BULLISH | 90% | 5/6/2026 | earnings beatBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | earnings beatBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | earnings beatBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | earnings beatBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | earnings beatBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | earnings beatBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | debt restructureBULLISH | 90% | 5/6/2026 | earnings beatBULLISH | 80% | 5/6/2026 | margin expansionNEUTRAL | 50% | 5/6/2026 | debt restructureMay 26May 26HIGHLOW
bullish
bearish
neutral

Signal Timeline

bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%
bullishMay 6

Revenue surged 85% YoY to $145.4 million driven by XDEMVY sales.

earnings beat
90%
bullishMay 6

Gross margins remained consistently high at 94%.

margin expansion
80%
neutralMay 6

Maintains a $75M credit facility with Pharmakon Advisors.

debt restructure
50%

Filing History

10-QMay 6, 2026

The Q1 2026 filing reveals a company at a critical inflection point. Tarsus has proven it can generate massive top-line growth and maintain elite margins, but it has yet to achieve GAAP profitability. The synthesis of the data suggests a high-reward trade-off: the bull case rests on the belief that the commercial ramp is sustainable and that the 2027 pipeline catalysts will diversify the risk. Conversely, the bear case highlights that the company is essentially a 'single-point-of-failure' business due to its API and customer concentration. Ultimately, the filing shows a transition from a speculative biotech to a commercial entity. While the $388.7 million liquidity cushion provides a safety net, the massive SG&A spend indicates that the cost of acquiring market share remains high. The coming quarters will determine if Tarsus can optimize its sales spend and diversify its customer base before the 2027 catalysts arrive.